Citations

Clear

4847 citation(s) found for "Tu, Eric".

Reality Check: Virtual Tools in Functional Vision Disorders (P10-17.014)
Kotay, Manisha , Eggenberger, Eric

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217339 Get It

Bridging Neuro-oncology and Gender-affirming Care: Clinical and Treatment Insights From a Multi-site Mayo Clinic Cohort (P6-6.003)
Schipani, Elke , Ser, Merve, ŞAHİN, Edanur , Uhm, Joon, Ruff, Michael, Neth, Bryan, Lehrer, Eric, Sener, Ugur, Uhm, Joon H. , Neth, Bryan J.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216907 Get It

Radiation Necrosis and Myelopathy Beyond the Targeted Field: A Case Series (P5-6.004)
ŞAHİN, Edanur , Carabenciov, Darin D., Webb, Mason J., Schultz, Sydney E., Breen, William, Sener, Ugur, Lehrer, Eric J.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215623 Get It

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial
Bashey, Asad, Logan, Brent R, Hill, LaQuisa C. , Symons, Heather J. , Farhadfar, Nosha , Grunwald, Michael R. , Pidala, Joseph A. , Dehn, Jason , Brunstein, Claudio, Arai, Sally , Leifer, Eric, He, Naya, Shaw, Bronwen E., Uberti, Joseph, Westervelt, Peter, Srour, Samer A, Pusic, Iskra , Vasu, Sumithira, Hayes‐Lattin, Brandon , Ciurea, Stefan O. , Horowitz, Mary M, Hill, LaQuisa C , Dehn, Jason G , Brunstein, Claudio , Juckett, Mark , Devine, Steven , Pusic, Iskra , Hayes-Lattin, Brandon , Ciurea, Stefan O , Lee, Stephanie J , Hogan, William J , Grunwald, Michael , Logan, Brent R. , Brunstein, Claudio G. , Shaw, Bronwen E. , Devine, Steven M. , Uberti, Joseph P., Srour, Samer A. , Vasu, Sumithira , Horowitz, Mary M. , Lee, Stephanie J. , Hogan, William J.

Mayo Clinic

Blood Advances | June 9, 2026 | Volume: 10 | Issue: 16 | Pages: 5543-5552

10.1182/bloodadvances.2026020355 | PMID 42263667 Get It

Abstract Newer approaches to control alloreactivity may produce similar transplant outcomes using HLA-mismatched donors vs HLA-matched unrelated donors (MUD). However, prospective comparisons are lacking. BMT CTN 1702 used a donor search prognosis score to assign patients to an 8/8 HLA MUD or the center’s preference of haploidentical related donors (HAPLO), mismatched unrelated donors (MMUD), or umbilical cord blood (UCB). Outcomes of MUD were compared to HAPLO, MMUD, and UCB transplantation after adjusting for covariates. Patients (n = 1179 [93% adults]) underwent transplantation with MUD (n = 772), HAPLO (n = 254), MMUD (n = 112), and UCB (n = 41) at a median of 3.7, 3.4, 3.9, and 3.8 months from enrollment. Posttransplant cyclophosphamide (PTCy) was used in 23.9%, 83.9%, 65.2%, and 0% of MUD, HAPLO, MMUD, and UCB. In multivariate analyses, compared to MUD, survival was lower for UCB (hazard ratio [HR], 2.65; P< .001) but not statistically different for HAPLO and MMUD (HRs, 1.08 and 1.18, respectively). Relapse risk was not significantly different by donor, but treatment-related mortality (HR, 3.31; P< .001) and disease-free survival (HR, 1.99; P = .002) were inferior for UCB but not different for HAPLO and MMUD than MUD. In patients who received PTCy, HAPLO and MMUD were associated with increased grade 3 or 4 acute graft-versus-host disease (GVHD; HR, 2.39 [P = .017] and 2.53 [P = .038], respectively) and chronic GVHD (HR, 1.71 for both; P = .028 and .080) than MUD, but other outcomes were not different. HAPLO or MMUD may be used to expedite transplantation when finding MUD is unlikely. This study was registered at www.clinicaltrials.gov as NCT03904134.
Outcomes of Patients With Favorable Intermediate Risk Gleason Grade Group 2 Prostate Cancer Undergoing Radical Prostatectomy in the MRI Era: Refining Active Surveillance Selection Criteria
Li, Eric V. , Ahmed, Eman E., Ahmed, Mohamed E., Wang, Michael K., Diaz‐Cobo, Julian, O'Byrne, Jamie, Cheville, John C., Shah, Paras H., Frank, Igor, Tollefson, Matthew K., Boorjian, S., Sharma, Vidit, Khanna, Abhinav, Karnes, R Jeffrey, Ahmed, Mohamed E., Diaz-Cobo, Julian, Cheville, John C. , Frank, Igor, Tollefson, Matthew K. , Sharma, Vidit , Karnes, R. Jeffrey

Mayo Clinic

The Prostate | June 8, 2026 | Volume: 86 | Issue: 12 | Pages: 1251-1257

10.1002/pros.70206 | PMID 42257571 Get It

ABSTRACT Background While guidelines state that patients with NCCN favorable intermediate risk (FIR) prostate cancer (PCa) may consider active surveillance (AS), there is a relative lack of longer term follow up data informing AS inclusion criteria of patients with Grade Group (GG) 2 prostate cancer in the MRI era. Here we evaluate patient outcomes from a MRI‐screened AS‐eligible cohort of FIR GG2 PCa receiving radical prostatectomy (RP). Methods Patients with prostate MRI, NCCN FIR GG2 PCa (PSA < 10 ng/mL, ≤ cT2a, < 50% core positivity), and no prior treatments who underwent RP from 2015 to 2023 were included from a prospectively maintained prostatectomy registry. Primary outcomes were adverse pathologic features (APF) at RP (GG3‐5, ≥ pT3a, or pN1) and biochemical recurrence (BCR). Logistic regression and Cox regression identified factors associated with APF at RP and time to BCR, respectively. Results Of 522 patients, 110 (21%) had APF at RP and 45 (9%) developed BCR with median follow up 2.4 years (IQR 1.3–2.8). On multivariable logistic regression, % Gleason pattern 4 (%GP4, %GP4 > 25% OR 2.14, 95% CI 1.28–3.58, p = 0.004) was independently associated with APF. On multivariable Cox regression for time to BCR, PSAD (HR 1.06, 95% CI 1.04–1.09, p < 0.001) and positive surgical margins (HR 1.06, 95% CI 1.09–3.78, p = 0.03) were independently associated with BCR. PIRADS, % core positivity, and specimen involvement were associated with neither APF nor BCR. Conclusions % Gleason pattern 4 > 25% and PSAD are the primary factors associated with adverse outcomes and should be considered for patients with FIR GG2 PCa considering active surveillance. PIRADS and measures of biopsy cancer volume were not associated with APF or BCR. These results may inform patient selection for active surveillance among patients with FIR GG2 PCa.
Defining rapid early progression in glioblastoma—A volumetric approach
Munlapudi, Vikram , Guzzino, Jacob , Crompton, David J., Agarwal, Shubhi , Lehrer, Eric J. , Kern, Shelby, Bogan, A.W., Vora, Sujay A., Quinones-Hinojosa, Alfredo, Sherman, Wendy J, Brown, P D, Laack, Nadia, Peterson, Jennifer, Uhm, Joon H, Ruff, Michael W. , Breen, William G. , Trifiletti, Daniel M. , Quinones-Hinojosa, Alfredo , Sener, Ugur T, Breen, Will , Trifiletti, Daniel M , Quiñones‐Hinojosa, Alfredo , Burns, Terry C. , Sherman, Wendy, Uhm, Joon H. , Sener, Uğur

Mayo Clinic

Neuro-Oncology Advances | June 6, 2026 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdag153 | PMID 42382820 Get It

Abstract Background The current treatment of glioblastoma involves resection followed by radiotherapy (RT) and temozolomide. Rapid early progression (REP) of tumor in the surgery-to-radiotherapy interval (SRI) has been described using categorical or semi-quantitative assessments and is associated with inferior clinical outcomes. This study seeks to establish and validate a quantitative definition for REP and examine how REP could inform future therapy. Methods Volumes of tumor and resection cavity at 3 time points—preoperative, postoperative and RT-planning (pre-RT)—were contoured among patients who had undergone standard of care. A minimal, but clinically appreciable, threshold for defining REP based on change in tumor volume was established, validated, and subsequently used to assess actionable predictors of REP and its prognostic value. Results An increase of &gt;2 cc in volume or a new satellite tumor between the post-operative to planning MRI was found to be a sensitive, pragmatic, and statistically significant cutoff for REP (P = .002). Actionable predictors such as SRI of 6 weeks and a &gt; 5 cc residual immediate post-operative tumor volume were found to be statistically significant predictors of REP. REP was also found to be a statistically significant prognostic indicator for overall survival (P = .002) and progression-free survival. Conclusion These findings support that an increase in tumor volume between post-operative and pre-RT MRI of &gt;2 cc is the ideal working definition of REP in this clinical setting. Furthermore, REP could serve as a prognostic ­biomarker to track treatment response. Additionally, 2 actionable predictors of REP, post-op residual tumor volume and SRI, are identified.
Reverse EUS-GJ: EUS guided decompression of Excluded Stomach Gastric Outlet Obstruction (eGOO) after Roux-en-Y Gastric Bypass Surgery
Valls, E Vargas, Gala, K, Ghanem, O, Abimansour, J, Han, S, Law, E, Dayyeh, B Abu, Chandrasekhara, V, Vargas, Eric J. , Ghanem, Omar M. , AbiMansour, Jad P. , Han, Samuel, Dayyeh, Barham K. Abu , Chandrasekhara, Vinay

Mayo Clinic

Endoscopy | June 5, 2026 | Volume: 58 | Issue: S 03 | Pages: S809-S810

10.1055/s-0046-1822242 Get It

Executive summary of American Radium Society Appropriate Use Criteria for the treatment of locoregionally recurrent rectal cancer
Miller, Eric D. , Jethwa, Krishan R. , Dozois, E, Jin, Zhaohui, Abood, G., Akselrod, Dmitriy, Attallah, Joseph, Codipilly, D Chamil, Anker, Christopher J., Hallemeier, Christopher L. , Kennedy, Timothy, Lee, Percy, Ling, Diane C., Newman, Neil, Sharma, Navesh, Small, William, Tchelebi, Leila, Russo, Suzanne , Akselrod, Dmitriy , Dozois, Eric, Akselrod, Dmitriy , Small, William , Jethwa, Krishan , Dozois, Eric J. , Abood, Gerard, Codipilly, Don C. , Anker, Christopher J. , Hallemeier, Christopher Leigh , Hassett, Leslie C. , Lee, Percy, Newman, Neil B. , Tchelebi, Leila T.

Mayo Clinic

Cancer | June 5, 2026 | Volume: 132 | Issue: 12 | Pages: No page available

10.1002/cncr.70464 | PMID 42246062 Get It

Abstract This literature‐based systematic review and associated guidelines provide evidence‐based paradigms for the management of locoregionally recurrent rectal cancer (LRRC). This multispecialty committee included gastrointestinal radiation and medical oncology, gastroenterology, radiology, and colorectal surgery. As is the standard, the previously described American Radium Society Appropriate Use Criteria methodology for this project was followed rigorously, with the Population, Intervention, Comparator, Outcome, Timing, and Study Design framework and Preferred Reporting Items for Systematic Reviews and Meta‐Analyses methodology to assess the evidence. RAND/University of California Los Angeles consensus methodology (modified Delphi) was used to rate the appropriateness of treatment options. Published between January 1, 2013, and July 16, 2025, 116 peer‐reviewed trials provided the evidence: 10 were well‐designed randomized phase 2/3 trials, 29 were moderately well designed trials that accounted for most common biases (matched cohort and phase 2), 76 trials had design limitations (retrospective), and one was a meta‐analysis. Clinical cases were created as examples to illustrate current acceptable management of LRRC. Treatment and prognosis are influenced by prior therapy and the site(s) and extent of LRRC. The ability to achieve a margin‐negative surgical resection is the ultimate determinant of survival and local control. Preoperative systemic therapy, radiation therapy, or a combination of the two can facilitate tumor downsizing and improve the likelihood of a margin‐negative resection. An individualized multidisciplinary approach is required to ensure the best outcome. Although this review does not suggest a major alteration of current practice, it provides reassuring evidence of the importance of combined‐modality therapy.
Stool Microbiota, Metabolites, and Fecal Incontinence in Women
Arya, Lily A. , Kashyap, Purna , Carnes, Megan U., Mathur, Ravi, Richter, Holly E., Andy, U., Jelovsek, J. Eric, Siddiqui, Nazema Y., Morrow, Casey D. , Lefkowitz, Elliot J. , Pol, William J. Van Der, Broeckling, Corey, Carper, Benjamin, Jeney, Sarah E.S., Zyczynski, Halina M. , Dyer, Keisha Y., Carberry, Cassandra, Mazloomdoost, D., Network, for the NICHD Pelvic Floor Disorders, Arya, Lily A. , Carnes, Megan Ulmer , Mathur, Ravi , Richter, Holly E , Andy, Uduak Umoh , Pol, William J. Van Der, Broeckling, Corey D. , Carper, Benjamin , Jeney, Sarah E.S. , Carberry, Cassandra, Mazloomdoost, Donna , Gantz, Marie G.

Mayo Clinic

Urogynecology | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/spv.0000000000001885 | PMID 42240124 Get It

Importance Stool metabolites influencing gut motility and sensation may contribute to fecal incontinence (FI). Objective The objective of this study was to test whether FI is associated with higher levels of butyrate and Clostridiales taxa in stool. Study Design Stool metabolites and microbiota were compared between 96 women with FI and 42 controls. FI frequency and subtype (urgency vs insensible) were measured using a 14-day bowel diary, St. Mark’s score, and the Accidental Bowel Leakage questionnaire. Metabolite analysis included targeted analysis (8 short-chain fatty acids including butyrate, 17 bile acids, and 8 tryptophan derivatives) and untargeted analysis. Stool microbiota were characterized using 16S rRNA gene sequencing. Multivariable and exploratory multiomics factor analysis were performed with statistical significance defined as false discovery rate (FDR) ≤0.10. Results The FI group had a higher proportion of Bristol stool types 2 and 6 than controls ( P = 0.005). The mean number of leaks for the FI group was 1.7 ± 1.7 per day, 38% had urgency FI, and 39% had insensible FI. There was no significant difference between groups in butyrate levels and Clostridiales taxa. Multiomics analysis identified glycerolipids (monoacylglycerols and diacylglycerols) associated with FI (FDR = 0.08). In addition, insensible FI was associated with glycerolipids, long-chain saturated and monounsaturated fatty acids, phospholipids, and dipeptides (FDR = 0.08–0.09). The top weighted microbiota associated with these metabolites were Lachnospiraceae and Ruminococcaceae; however, these taxa were not directly associated with FI. Conclusion Butyrate and Clostridiales were not associated with FI. Novel stool metabolite signatures were identified, suggesting new biological pathways and potential therapeutic targets for FI.